Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Caterpillar Inc (CAT) vs Merck & Co., Inc. (MRK) Price & Performance

Caterpillar IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Caterpillar Inc vs Merck & Co., Inc. — how do they compare? Caterpillar Inc trades at $855.88 (market cap $385.01B), while Merck & Co., Inc. trades at $130.11 (market cap $323.00B). The key difference: Caterpillar Inc is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.

CATMRK
Market Cap
$385.01B$323.00B
Sector
IndustrialsHealth
52-Week High
$1.06K$131.84
52-Week Low
$407.79$77.60
Enterprise Value
$423.45B$369.77B
Dividend Yield
0.78%2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Caterpillar Inc

Caterpillar (CAT) trades at $843.37, up 0.14% on the day, with strong year-to-date performance driven by robust earnings beats and AI data center demand. The stock shows a bearish technical signal but maintains solid fundamentals, including a net income margin of 14.51% and ROE of 56.99%. Recent news highlights growth from power and energy segments, with a dividend increase expected in June 2026.

Outlook remains positive due to earnings momentum and infrastructure tailwinds, though elevated valuation ratios like a P/E of 36.07 pose risks. Analyst consensus is bullish with a $1,010 price target, but investors should monitor economic cycles and competitive pressures that could impact future performance.

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Caterpillar Inc

Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.

Read more on CAT

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK